Projected Income Statement: Elliptic Laboratories ASA

Forecast Balance Sheet: Elliptic Laboratories ASA

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Net Debt 1 -201 -166 -89.7 -57 -43.1 -67 -50.9 -43.1
Change - 17.41% 45.96% 36.45% 24.39% -55.6% 24.03% 15.32%
Announcement Date 3/10/22 2/17/23 2/15/24 2/27/25 2/26/26 - - -
1NOK in Million
Estimates

Cash Flow Forecast: Elliptic Laboratories ASA

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
CAPEX 1 17.61 23.33 25.48 30.72 29.08 25 25 28
Change - 32.46% 9.22% 20.56% -5.32% -14.04% 0% 12%
Free Cash Flow (FCF) 1 -28.43 -36.08 - - -23.09 -25 -10 -1
Change - -26.91% - - - -8.28% 60% 90%
Announcement Date 3/10/22 2/17/23 2/15/24 2/27/25 2/26/26 - - -
1NOK in Million
Estimates

Forecast Financial Ratios: Elliptic Laboratories ASA

Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028

Profitability

        
EBITDA Margin (%) -4.49% -59.19% -49.06% 19.04% -20.13% -5.79% 14.48% 23.91%
EBIT Margin (%) -17.67% -80.92% -72.81% 3.57% -44.23% -30.82% -7.25% 5.25%
EBT Margin (%) -20.77% -75.49% -68.58% 12.92% -56.68% -33.79% -6.83% 5.31%
Net margin (%) -17.7% -61.54% -55.4% 6.79% -135.3% -31.36% -5.33% 4.14%
FCF margin (%) -45.11% -69.31% - - -22.47% -24.47% -8.24% -0.66%
FCF / Net Income (%) 254.87% 112.62% - - 16.61% 78% 154.69% -15.97%

Profitability

        
ROA - - - - - - - -
ROE -4.2% -9.7% -11.96% 2.84% -54.86% - - 2.76%

Financial Health

        
Leverage (Debt/EBITDA) - - - - - - - -
Debt / Free cash flow - - - - - - - -

Capital Intensity

        
CAPEX / Current Assets (%) 27.94% 44.81% 37.29% 23.28% 28.31% 24.47% 20.61% 18.51%
CAPEX / EBITDA (%) -622.48% -75.7% -76.01% 122.29% -140.63% -422.54% 142.35% 77.41%
CAPEX / FCF (%) -61.94% -64.64% - - -125.96% -100% -250% -2,800%

Items per share

        
Cash flow per share 1 - - - - - - - -
Change - - - - - - - -
Dividend per Share 1 - - - - - - - -
Change - - - - - - - -
Book Value Per Share 1 3.301 3.134 2.929 3.09 1.786 1.683 1.676 1.765
Change - -5.06% -6.53% 5.5% -42.22% -5.74% -0.41% 5.33%
EPS 1 -0.11 -0.31 -0.36 0.09 -1.32 -0.2475 -0.0494 0.0473
Change - -181.82% -16.13% 125% -1,566.67% 81.25% 80.05% 195.81%
Nbr of stocks (in thousands) 103,842 104,074 104,838 105,275 105,287 126,337 126,337 126,337
Announcement Date 3/10/22 2/17/23 2/15/24 2/27/25 2/26/26 - - -
1NOK
Estimates
2026 *2027 *
P/E -10.2x -51.1x
PBR 1.5x 1.5x
EV / Sales 2.46x 2.21x
Yield - -

EPS & Dividend

Y-o-Y evolution of P/E

Year-on-year evolution of the Yield

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.520NOK
Average target price
4.800NOK
Spread / Average Target
+90.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ELABS Stock
  4. Financials Elliptic Laboratories ASA